Saturday 17 October 2026
Export CTXR’s income statement to Excel — free account
Citius Pharmaceuticals, Inc.
CTXR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 57.5% and free cash flow fell 60.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.46
0.00
0.00%
Follow CTXR
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 63.75 | 64.00 | 23.40 | 10.00 | 10.38 | 25.00 | 19.25 | 15.00 | 2.44 | 0.63 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 937.50 | 365.63 | 115.00 | 44.75 | 49.25 | 114.00 | 50.25 | 42.75 | 26.75 | 4.51 | |||||
| People | |||||||||||||||
| People | Employees | 6 | 7 | 7 | 9 | 10 | 15 | 21 | 22 | 23 | 23 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | |||||
| EBT | (8) | (10) | (13) | (16) | (18) | (23) | (33) | (32) | (39) | (39) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (8) | (10) | (13) | (16) | (18) | (23) | (34) | (33) | (39) | (40) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (57.24) | (47.36) | (29.25) | (17.12) | (11.25) | (5.75) | (5.75) | (5.50) | (5.97) | (3.38) | |||||
| Cash flow | (40.72) | (36.35) | (26.36) | (15.42) | (10.81) | (5.58) | (4.85) | (4.80) | (4.19) | (2.40) | |||||
| Capex | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (40.72) | (36.36) | (26.36) | (15.42) | (10.81) | (5.58) | (4.85) | (4.80) | (4.19) | (2.40) | |||||
| Book value | 115.71 | 100.08 | 64.91 | 33.67 | 21.49 | 30.57 | 17.70 | 15.11 | 11.02 | 7.01 | |||||
| Shares, m | 0 | 0 | 0 | 1 | 2 | 4 | 6 | 6 | 7 | 11 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (6) | (8) | (11) | (12) | (17) | (24) | (28) | (29) | (28) | (27) | ||||
| Capex | — | 0 | — | — | 0 | 0 | — | — | — | — | |||||
| Free cash flow | (6) | (8) | (11) | (12) | (17) | (24) | (28) | (29) | (28) | (27) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | (4) | 1 | 7 | 3 | 10 | 69 | 40 | 29 | (22) | (17) | ||||
| Total debt | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | — | — | |||||
| Net debt | 0 | (3) | (9) | (8) | (14) | (70) | (42) | (26) | (3) | (4) | |||||
| Shareholders’ equity | 17 | 22 | 28 | 27 | 34 | 133 | 103 | 91 | 74 | 78 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (73.12) | (44.79) | (45.20) | (45.91) | (43.59) | (26.32) | (26.24) | (30.97) | (36.49) | (30.24) | ||||
| ROIC | (28.27) | (33.30) | (46.13) | (50.62) | (55.41) | (23.45) | (33.74) | (35.35) | (37.05) | (32.86) | |||||
| ROE | (102.85) | (53.65) | (50.33) | (56.57) | (57.70) | (29.44) | (28.48) | (34.58) | (48.55) | (49.38) | |||||
Negative figures in brackets.
Latest quarter Jun 2026
Charts ten years each
Citius Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ICU SeaStar Medical Holding Corporation | $13.5M | — (loss-making) | — (loss-making) | +81.95% (above 0%: growing) | n/m | +0.43% (above 0%: growing) | 91.22% | (616.42%) | Compare |
| HIND Vyome Holdings, Inc. | $13.4M | 0.0× | — (loss-making) | −46.00% (below 0%: shrinking) | n/m | −195.04% (below 0%: shrinking) | 43.33% | (3,194.81%) | Compare |
| ALLR Allarity Therapeutics, Inc. | $13.2M | — (loss-making) | — (loss-making) | — | n/m | +53.22% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CTXR Citius Pharmaceuticals, Inc. | $12.6M | — (loss-making) | — | — | n/m | −60.50% (below 0%: shrinking) | 67.07% | (785.39%) | |
| CASIF CASI Pharmaceuticals Inc. | $12.4M | — (loss-making) | — (loss-making) | −45.93% (below 0%: shrinking) | n/m | −23,251.69% (below 0%: shrinking) | 51.14% | (147.67%) | Compare |
| AEON AEON Biopharma, Inc. | $12.1M | — (loss-making) | — | — | n/m | −76.85% (below 0%: shrinking) | — | 0.00% | Compare |
| ASBP Aspire-Lakewood Holdings, Inc. | $12.1M | 0.2× | — | — | n/m | −85.54% (below 0%: shrinking) | (47.70%) | (4,244.37%) | Compare |
| ACTU Actuate Therapeutics, Inc. | $12.0M | — (loss-making) | — | — | n/m | −5.54% (below 0%: shrinking) | — | 0.00% | Compare |
| PLUR Pluri Inc. | $11.9M | — (loss-making) | — (loss-making) | −15.83% (below 0%: shrinking) | n/m | +25.03% (above 0%: growing) | 58.51% | (1,655.52%) | Compare |
| Median of peers | $12.3M | — | — | −30.88% | — | −41.19% | 54.82% | (382.04%) |
Citius Pharmaceuticals, Inc. (CTXR) key facts
- Citius Pharmaceuticals, Inc. (CTXR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CTXR traded at $0.46, a market capitalization of $12.6 million.
- Return on equity was −49.4% and debt-to-equity 0.08.
Citius Pharmaceuticals, Inc. (CTXR) Latest News
No news at this impact. Lower the threshold for more.